Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120

Virology

Volumn 433, Issue 2, 2012, Pages 308-319

  Férir, Geoffrey ^a   Hänchen, Anne ^b   François, Katrien O ^a   Hoorelbeke, Bart ^a   Huskens, Dana ^a   Dettner, Frank ^b   Süssmuth, Roderich D ^b   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Alanine scan; CD4 receptor; CD4 gp120 inhibitor; Feglymycin; Gp120; HIV; Resistance; Surface plasmon resonance (SPR)

Indexed keywords

ALANINE; ASPARTIC ACID; CYCLOTRIAZADISULFONAMIDE; DEXTRAN SULFATE; ENFUVIRTIDE; FEGLYMYCIN; FEGLYMYCIN DERIVATIVE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RPA T4; NEVIRAPINE; PLERIXAFOR; POLYPEPTIDE ANTIBIOTIC AGENT; PRO 2000; RITONAVIR; SULFONAMIDE; TENOFOVIR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INTERACTION; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ENTRY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIGENS, CD4; BACTERIAL PROTEINS; CELL LINE; DRUG DISCOVERY; GIANT CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; PROTEINS; VIRUS INTERNALIZATION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1; STREPTOMYCES;

EID: 84867193540     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.08.007     Document Type: Article

References (51)

1. Alen M.M., Kaptein S.J., De Burghgraeve T., Balzarini J., Neyts J., Schols D. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology 2009, 387:67-75.
2. Balzarini J., Van Herrewege Y., Vermeire K., Vanham G., Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 2007, 71:3-11.
3. Bertaux C., Daelemans D., Meertens L., Cormier E.G., Reinus J.F., Peumans W.J., Van Damme E.J., Igarashi Y., Oki T., Schols D., Dragic T., Balzarini J. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate binding agents but not by polyanions. Virology 2007, 366:40-50.
4. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., Gulakowski R.J., Wu L., Rivera M.I., Laurencot C.M., Currens M.J., Cardellina J.H., Buckheit R.W., Nara P.L., Pannell L.K., Sowder R.C., Henderson L.E. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 1997, 41:1521-1530.
5. Bray B.L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2003, 2:587-593.
6. Bunkóczi G., Vértesy L., Sheldrick G.M. The antiviral antibiotic feglymycin: first direct-methods solution of a 1000+ equal-atom structure. Angew. Chem. Int. Ed. Engl. 2005, 44:1340-1342.
7. Celum C.L. HIV preexposure prophylaxis: new data and potential use. Top. Antivir. Med. 2011, 19:181-185.
8. Constantine K.L., Friedrichs M.S., Detlefsen D., Nishio M., Tsunakawa M., Furumai T., Ohkuma H., Oki T., Hill S., Bruccoleri R.E. High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion. J. Biomol. NMR 1995, 5:271-286.
9. Coombs R.W., Reichelderfer P.S., Landay A.L. Recent observations on HIV type-1 infection in the genital tract of men and women. Acq. Immun. Def. Synd. 2003, 17:455-480.
10. D'Cruz O.J., Uckun F.M. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J. Antimicrob. Chemother. 2006, 57:411-423.
11. De Vreese K., Kofler-Mongold V., Leutgeb C., Weber V., Vermeire K., Schacht S., Anné J., De Clercq E., Datema R., Werner G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 1996, 70:689-696.
12. Detlefsen D.J., Hill S.E., Volk K.J., Klohr S.E., Tsunakawa M., Furumai T., Lin P.F., Nishio M., Kawano K., Oki T., Lee M.S. Siamycins I and II, new anti-HIV-1 peptides: II. Sequence analysis and structure determination of siamycin I. J. Antibiot. (Tokyo) 1995, 48:1515-1517.
13. Dettner F., Hänchen A., Schols D., Toti L., Nusser A., Süssmuth R.D. Total synthesis of the antiviral peptide antibiotic feglymycin. Angew. Chem. Int. Ed. Engl. 2009, 48:1856-1861.
14. Dwyer J.J., Wilson K.L., Davison D.K., Freel S.A., Seedorff J.E., Wring S.A., Tvermoes N.A., Matthews T.J., Greenberg M.L., Delmedico M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Nat. Acad. Sci. U.S.A. 2007, 104:12772-12777.
15. Eggink D., Bontjer I., Langedijk J.P., Berkhout B., Sanders R.W. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J. Virol. 2011, 85:10785-10797.
16. Elander R.P. Industrial production of Β-lactam antibiotics. Appl. Microbiol. Biotechnol. 2003, 61:385-392.
17. Esté J.A., Schols D., De Vreese K., Van Laethem K., Vandamme A.M., Desmyter J., De Clercq E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 1997, 52:98-104.
18. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., Cornelissen I.L., Nottet H.S., KewalRamani V.N., Littman D.R., Figdor C.G., van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
19. Granelli-Piperno A., Pritsker A., Pack M., Shimeliovich I., Arrighi J.F., Park C.G., Trumpfheller C., Piguet V., Moran T.M., Steinman R.M. Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J. Immunol. 2005, 175:4265-4273.
20. Hladik F., Doncel G.F. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res. 2010, 88(1):S3-S9.
21. Hladik F., McElrath M.J. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 2008, 8:447-457.
22. Hoorelbeke B., Huskens D., Férir G., François K.O., Takahashi A., Van Laethem K., Schols D., Tanaka H., Balzarini J. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob. Agents Chemother. 2010, 54:3287-3301.
23. Huskens D., Van Laethem K., Vermeire K., Balzarini J., Schols D. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 2007, 360:294-304.
24. Huskens D., Vermeire K., Profy A.T., Schols D. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res. 2009, 84:38-47.
25. Huskens D., Férir G., Vermeire K., Kehr J.C., Balzarini J., Dittmann E., Schols D. Microvirin, a novel {alpha}(1,2)-mannose-specific lectin isolated from microcystis aeruginosa, has comparable anti-HIV-1 activity as cyanovirin-N, but a much higher safety profile. J. Biol. Chem. 2010, 285:24845-24854.
26. Joly V., Jidar K., Tatay M., Yeni P. Enfuvirtide: from basic investigations to current clinical use. Expert Opin. Pharmacother. 2010, 11:2701-2713.
27. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
28. Lederman M.M., Offord R.E., Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 2006, 6:371-382.
29. Lin P.F., Blair W., Wang T., Spicer T., Guo Q., Zhou N., Gong Y.F., Heidi Wang H.G., Rose R., Yamanaka G., Robinson B., Li C.B., Fridell R., Deminie C., Demers G., Yang Z., Zadjura L., Meanwell N., Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:11013-11018.
30. Lin P.F., Samanta H., Bechtold C.M., Deminie C.A., Patick A.K., Alam M., Riccardi K., Rose R.E., White R.J., Colonno R.J. Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrob. Agents Chemother. 1996, 40:133-138.
31. Matsuzaki K., Ogino T., Sunazuka T., Tanaka H., Omura S. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from streptomyces sp. II. Structure elucidation of chloropeptin I. J. Antibiot. (Tokyo) 1997, 50:66-69.
32. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 2004, 3:215-225.
33. Münch J., Ständker L., Adermann K., Schulz A., Schindler M., Chinnadurai R., Pöhlmann S., Chaipan C., Biet T., Peters T., Meyer B., Wilhelm D., Lu H., Jing W., Jiang S., Forssmann W.G., Kirchhoff F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007, 129:263-275.
34. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., Janssen P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343:470-474.
35. Princen K., Hatse S., Vermeire K., De Clercq E., Schols D. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology 2004, 1:2.
36. Rusconi S., Moonis M., Merrill D.P., Pallai P.V., Neidhardt E.A., Singh S.K., Willis K.J., Osburne M.S., Profy A.T., Jenson J.C., Hirsch M.S. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 1996, 40:234-236.
37. Sallé B., Brochard P., Bourry O., Mannioui A., Andrieu T., Prevot S., Dejucq-Rainsford N., Dereuddre-Bosquet N., Le Grand R. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 2010, 202:337-344.
38. Schols D., Struyf S., Van Damme J., Esté J.A., Henson G., De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 1997, 186:1383-1388.
39. Scordi-Bello I.A., Mosoian A., He C., Chen Y., Cheng Y., Jarvis G.A., Keller M.J., Hogarty K., Waller D.P., Profy A.T., Herold B.C., Klotman M.E. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 2005, 49:3607-3615.
40. Sigal A., Kim J.T., Balazs A.B., Dekel E., Mayo A., Milo R., Baltimore D. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477:95-98.
41. Tilton J.C., Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010, 85:91-100.
42. Tsunakawa M., Hu S.L., Hoshino Y., Detlefson D.J., Hill S.E., Furumai T., White R.J., Nishio M., Kawano K., Yamamoto S., Fukagawa Y., Oki T. Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization. J. Antibiot. (Tokyo) 1995, 48:433-434.
43. Van Laethem K., Schrooten Y., Lemey P., Van Wijngaerden E., De Wit S., Van Ranst M., Vandamme A.M. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J. Virol. Methods 2005, 123:25-34.
44. Vermeire K., Princen K., Hatse S., De Clercq E., Dey K., Bell T.W., Schols D. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. Acq. Immun. Def. Synd. 2004, 18:2115-2125.
45. Vermeire K., Van Laethem K., Janssens W., Bell T.W., Schols D. Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility. J. Virol. 2009, 83:9577-9583.
46. Vértesy L., Aretz W., Knauf M., Markus A., Vogel M., Wink J. Feglymycin, a novel inhibitor of the replication of the human immunodeficiency virus. Fermentation, isolation and structure elucidation. J. Antibiot. (Tokyo) 1999, 52:374-382.
47. Wang H.G., Williams R.E., Lin P.F. A novel class of HIV-1 entry inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Curr. Pharm. Des. 2004, 10:1785-1793.
48. Wu X., Zhou T., O'Dell S., Wyatt R.T., Kwong P.D., Mascola J.R. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 2009, 83:10892-10907.
49. Wu L., KewalRamani V.N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 2006, 6:859-868.
50. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004, 4:199-210.
51. (visited December 22th, 2011). http://www.who.int/hiv/data/en/index.html.